INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Corporate insider
IK

Issa Mohamed Khairie

EVP, Head of US OncologyCIK 0002050035

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 1
Max Insider Score18
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Grant or award
A—
14.2K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    INCYTE CORPEVP, Head of US Oncology · Jan 8, 2026
9
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Tax withholding · 10b5-1 plan
F
$881K
8,264 sh
Jan 6, 2026
Jan 8, 2026
traded Jan 6, 2026
+2d
SEC FORM 4

Evidence

18
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$1.18M
10.9K sh
Jan 7, 2026Jan 8, 2026
traded Jan 7, 2026
+1dSEC FORM 4

Evidence